Aileron reports Q4 net loss $7.3M; expects LTI-03 topline results in Q3 2024

Rein Therapeutics, Inc.

2024-Q1 EPS reported -$0.86

Net loss Q4 2023 $7.3M ($1.54 per share) vs $4.5M ($1.00) in Q4 2022; FY 2023 net loss $3.42 per share vs $6.02.
Cash, cash equivalents and investments $17.3M at Dec 31, 2023; runway into Q4 2024.
Completed merger with Lung Therapeutics in Oct 2023; raised ~$18M in private placement.
Appointed Brian Windsor as President and CEO in March 2024 (ex-CEO of Lung).
LTI-03 Phase 1b topline results in IPF expected Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rein Therapeutics, Inc. reported full year ended December 31, 2023 results: EPS $3.42 per share.

Period: full year ended December 31, 2023
EPS: $3.42 per share
Result: reported results

Exact text from the filing

The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rein Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: net income $7.3 million, EPS $1.54 per share.

Period: the fourth quarter ended December 31, 2023
Net income: $7.3 million
EPS: $1.54 per share
Result: reported results

Exact text from the filing

Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022. The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.

View on SEC.gov

322 earnings releases filed in the last 30 days. Browse all earnings releases →

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-096389

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.